MYOMO, INC. MYO

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NYSE

We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. We primarily provide devices directly to patients and bill their insurance companies directly, a sales channel we refer to as direct billing. Under direct billing, we evaluate, measure and fit the MyoPro devices using our own clinical staff or as circumstances dictate, utilize the clinical consulting services of orthotics and prosthetics, or O&P. We also sell our products through various other sales channels, including through O&P providers, which we expect to be a larger contributor to revenue in the future, the Veterans Administration, or VA, and to certain accounts and geographic markets outside the United States. We operate as one business segment.

Last close 1.44 2026-09-04
Market cap $57.0M 2026-06-30 share count
52-week range 0.60 - 1.89

Valuation FY2025 figures against the last close

P/S1.4x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-0.37

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $40.9M$32.6M$19.2M$15.6M$13.9M$7.6M$3.8M$2.4M$1.6M$1.1M
Cost of revenue $14.0M$9.4M$6.1M$5.3M$3.5M$2.6M$1.4M$728.3K$505.3K$282.2K
Gross profit $26.9M$23.2M$13.2M$10.3M$10.3M$5.0M$2.4M$1.7M$1.1M$821.1K
R&D $6.9M$4.8M$2.6M$2.5M$2.6M$1.7M$1.7M$1.8M$1.8M$1.1M
SG&A $14.0M$12.4M$9.7M$18.4M$18.0M$13.8M$11.5M$10.4M$5.8M$3.0M
Total operating expenses $41.3M$29.4M$21.4M$20.9M$20.6M$15.5M$13.2M$12.2M$7.6M$4.1M
Operating income -$14.4M-$6.2M-$8.2M-$10.7M-$10.3M-$10.5M-$10.8M-$10.5M-$6.5M-$3.3M
Pre-tax income -$15.1M-$5.8M-$8.0M-$10.7M-$10.3M-$11.6M-$12.1M-$3.6M
Income tax $504.5K$365.6K$156.0K$69.9K$88.9K$0$0
Net income -$15.6M-$6.2M-$8.1M-$10.7M-$10.4M-$11.6M-$10.7M-$10.3M-$12.1M-$3.6M
EPS, basic -0.37-0.16-0.28-1.52-1.89
EPS, diluted -0.37-0.16-0.28-1.52-1.89-3.67-20.79-25.18-2.93-4.13
Shares, diluted (wtd. avg.) $41.9M$37.8M$29.5M$7.1M$5.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $14.1M$24.4M$6.9M$5.3M$15.5M$12.2M$4.5M$6.5M$13.0M$797.2K
Short-term investments $4.3M$493.0K$2.0M$0
Receivables $4.1M$3.8M$2.4M$1.9M$2.0M$924.9K$424.3K$382.3K$297.0K$114.5K
Inventory $3.1M$3.2M$1.8M$1.4M$808.3K$707.1K$439.5K$256.1K$201.2K$82.4K
Total current assets $27.6M$32.8M$13.7M$9.2M$19.1M$14.4M$6.1M$7.9M$13.8M$1.1M
Property, plant and equipment $2.2M$1.3M$175.8K$194.3K$275.3K$95.0K$155.0K$187.5K$77.2K$21.6K
Total assets $38.6M$42.2M$14.6M$10.2M$20.1M$14.7M$6.6M$8.3M$14.0M$1.7M
Accounts payable $5.8M$9.0M$4.9M$3.2M$3.9M$2.8M$1.7M$1.7M
Short-term debt $3.0M$3.0M$1.8M
Total current liabilities $8.3M$10.2M$5.5M$3.6M$4.3M$2.9M$3.9M$1.9M$1.5M$3.0M
Long-term debt $11.2M$0$889.0K
Total liabilities $27.2M$17.5M$5.6M$3.8M$4.7M$3.1M$4.8M$1.9M$1.5M$6.5M
Retained earnings -$118.7M-$103.1M-$96.9M-$88.8M-$78.1M-$67.7M-$56.1M-$45.3M-$35.0M-$22.9M
Total equity $11.4M$24.7M$9.0M$6.4M$15.4M$11.6M$6.4M$6.4M$12.4M-$17.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$14.5M-$3.3M-$6.2M-$10.2M-$9.5M-$9.0M-$10.3M-$9.6M-$6.2M-$3.2M
Depreciation and amortisation $859.4K$205.9K$164.3K$192.8K$146.0K$105.4K$95.1K$69.7K$11.4K$7.7K
Stock-based compensation $2.1M$874.4K$1.1M$1.2M$1.1M$614.3K$908.0K$814.7K$279.5K$94.1K
Capital expenditure $1.7M$1.4M$145.8K$111.8K$326.5K$45.8K$52.0K$126.9K$67.0K$1.9K
Investing cash flow -$7.1M$260.0K-$2.0M-$310.8K-$326.5K-$45.8K-$52.0K-$126.9K-$67.0K-$1.9K
Financing cash flow $11.4M$20.9M$9.7M$376.9K$13.2M$16.8M$8.3M$3.3M$18.4M$3.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-223981.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $129.55B 46.6x 20.5%
EW Edwards Lifesciences Corp $51.82B 49.1x 11.5%
STE STERIS plc $21.90B 28.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.71B 27.6x 7.2%
ALGN ALIGN TECHNOLOGY INC $11.27B 28.1x 0.9%
MSA MSA Safety Inc $7.28B 26.6x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.21B 27.1%
CDRE Cadre Holdings, Inc. $1.27B 29.2x 7.5%